170 related articles for article (PubMed ID: 16445122)
1. The complexities inherent in attempts to decrease drug clearance by blocking sites of CYP-mediated metabolism.
Fisher MB; Henne KR; Boer J
Curr Opin Drug Discov Devel; 2006 Jan; 9(1):101-9. PubMed ID: 16445122
[TBL] [Abstract][Full Text] [Related]
2. MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist.
Cruciani G; Carosati E; De Boeck B; Ethirajulu K; Mackie C; Howe T; Vianello R
J Med Chem; 2005 Nov; 48(22):6970-9. PubMed ID: 16250655
[TBL] [Abstract][Full Text] [Related]
3. Cytochromes P450 and drug discovery.
Lamb DC; Waterman MR; Kelly SL; Guengerich FP
Curr Opin Biotechnol; 2007 Dec; 18(6):504-12. PubMed ID: 18006294
[TBL] [Abstract][Full Text] [Related]
4. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model.
Houston JB; Kenworthy KE
Drug Metab Dispos; 2000 Mar; 28(3):246-54. PubMed ID: 10681367
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 metabolism and inhibition: analysis for drug discovery.
Jones BC; Middleton DS; Youdim K
Prog Med Chem; 2009; 47():239-63. PubMed ID: 19328293
[No Abstract] [Full Text] [Related]
6. Cytochrome P450-mediated metabolism in the human gut wall.
Thelen K; Dressman JB
J Pharm Pharmacol; 2009 May; 61(5):541-58. PubMed ID: 19405992
[TBL] [Abstract][Full Text] [Related]
7. Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage.
Emoto C; Murase S; Iwasaki K
Xenobiotica; 2006 Aug; 36(8):671-83. PubMed ID: 16891248
[TBL] [Abstract][Full Text] [Related]
8. Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs.
Crivori P; Poggesi I
Eur J Med Chem; 2006 Jul; 41(7):795-808. PubMed ID: 16644065
[TBL] [Abstract][Full Text] [Related]
9. Cytochromes P450: decision-making tools for personalized therapeutics.
Murray M; Petrovic N
Curr Opin Mol Ther; 2006 Dec; 8(6):480-6. PubMed ID: 17243482
[TBL] [Abstract][Full Text] [Related]
10. Human CYPs involved in drug metabolism: structures, substrates and binding affinities.
Lewis DF; Ito Y
Expert Opin Drug Metab Toxicol; 2010 Jun; 6(6):661-74. PubMed ID: 20402561
[TBL] [Abstract][Full Text] [Related]
11. Failure in drug development: the role of inhibition and induction of cytochrome P450 enzymes.
Hengstler JG; Bolt HM
Arch Toxicol; 2008 Oct; 82(10):665-6. PubMed ID: 18751968
[No Abstract] [Full Text] [Related]
12. The pivotal role of hepatocytes in drug discovery.
Soars MG; McGinnity DF; Grime K; Riley RJ
Chem Biol Interact; 2007 May; 168(1):2-15. PubMed ID: 17208208
[TBL] [Abstract][Full Text] [Related]
13. Effects of water deprivation on drug pharmacokinetics: correlation between drug metabolism and hepatic CYP isozymes.
Lee JH; Oh JM; Lee MG
Arch Pharm Res; 2008 Aug; 31(8):951-64. PubMed ID: 18787780
[TBL] [Abstract][Full Text] [Related]
14. In silico predictive metabolism: a structural/electronic filter method.
Harris DL
Curr Opin Drug Discov Devel; 2004 Jan; 7(1):43-8. PubMed ID: 14982147
[TBL] [Abstract][Full Text] [Related]
15. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective.
Bjornsson TD; Callaghan JT; Einolf HJ; Fischer V; Gan L; Grimm S; Kao J; King SP; Miwa G; Ni L; Kumar G; McLeod J; Obach SR; Roberts S; Roe A; Shah A; Snikeris F; Sullivan JT; Tweedie D; Vega JM; Walsh J; Wrighton SA;
J Clin Pharmacol; 2003 May; 43(5):443-69. PubMed ID: 12751267
[TBL] [Abstract][Full Text] [Related]
16. The use of deuterium isotope effects to probe the active site properties, mechanism of cytochrome P450-catalyzed reactions, and mechanisms of metabolically dependent toxicity.
Nelson SD; Trager WF
Drug Metab Dispos; 2003 Dec; 31(12):1481-98. PubMed ID: 14625345
[TBL] [Abstract][Full Text] [Related]
17. QSAR of cytochrome inhibitors.
Roy K; Roy PP
Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1245-66. PubMed ID: 19708826
[TBL] [Abstract][Full Text] [Related]
18. Electrochemically driven drug metabolism by membranes containing human cytochrome P450.
Mie Y; Suzuki M; Komatsu Y
J Am Chem Soc; 2009 May; 131(19):6646-7. PubMed ID: 19402636
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling.
Gibson CR; Bergman A; Lu P; Kesisoglou F; Denney WS; Mulrooney E
Xenobiotica; 2009 Sep; 39(9):637-48. PubMed ID: 19480559
[TBL] [Abstract][Full Text] [Related]
20. Challenges in exploring the cytochrome P450 system as a source of variation in canine drug pharmacokinetics.
Martinez MN; Antonovic L; Court M; Dacasto M; Fink-Gremmels J; Kukanich B; Locuson C; Mealey K; Myers MJ; Trepanier L
Drug Metab Rev; 2013 May; 45(2):218-30. PubMed ID: 23432217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
